Zevra Therapeutics, Inc. Cost, Amortization
Zevra Therapeutics, Inc. (ZVRA) reported Cost, Amortization of $1.61 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-13.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSoldAmortization · last filed 2025-05-13
- Zevra Therapeutics, Inc. cost, amortization for the quarter ending 2025-03-31 was $1.61M, a 5.69% increase year-over-year.
- Zevra Therapeutics, Inc. cost, amortization for the quarter ending 2024-12-31 was $1.62M, a 109.33% increase year-over-year.
- Zevra Therapeutics, Inc. cost, amortization for the quarter ending 2024-09-30 was $1.54M.
- Zevra Therapeutics, Inc. cost, amortization for the quarter ending 2024-06-30 was $1.55M.
- Zevra Therapeutics, Inc. cost, amortization for fiscal 2024 was $6.24M, a 707.64% increase from fiscal 2023.
- Zevra Therapeutics, Inc. cost, amortization for fiscal 2023 was $772.00K.
| Period end | Cost, Amortization 3 month | Cost, Amortization 6 month | Cost, Amortization 9 month | Cost, Amortization 12 month |
|---|---|---|---|---|
| 2025-03-31 | $1.61M 10-Q · filed 2025-05-13 | $3.23M derived: sum of 2 quarters · filed 2025-05-13 | $4.78M derived: sum of 3 quarters · filed 2025-05-13 | $6.32M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $3.16M derived: sum of 2 quarters · filed 2025-03-12 | $4.71M derived: sum of 3 quarters · filed 2025-03-12 | $6.24M 10-K · filed 2025-03-12 |
| 2024-09-30 | $1.54M 10-Q · filed 2024-11-13 | $3.09M derived: sum of 2 quarters · filed 2024-11-13 | $4.62M 10-Q · filed 2024-11-13 | $5.39M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-06-30 | $1.55M 10-Q · filed 2024-08-14 | $3.07M 10-Q · filed 2024-08-14 | $3.85M derived: sum of 3 quarters · filed 2025-05-13 | $3.85M derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-03-31 | $1.53M 10-Q · filed 2025-05-13 | $2.30M derived: sum of 2 quarters · filed 2025-05-13 | $2.30M derived: sum of 3 quarters · filed 2025-05-13 | $2.30M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $772.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $772.00K derived: sum of 2 quarters · filed 2025-03-12 | $772.00K derived: sum of 3 quarters · filed 2025-03-12 | $772.00K 10-K · filed 2025-03-12 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |